Analysts’ Weekly Ratings Updates for Kalaris Therapeutics (KLRS)

Several brokerages have updated their recommendations and price targets on shares of Kalaris Therapeutics (NASDAQ: KLRS) in the last few weeks:

• 12/23/2025 – Kalaris Therapeutics is now covered by analysts at Chardan Capital. They set a “buy” rating and a $19.00 price target on the stock.
• 12/23/2025 – Kalaris Therapeutics is now covered by analysts at Chardan Capital. They set a “buy” rating and a $19.00 price target on the stock.
• 12/22/2025 – Kalaris Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Kalaris Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/18/2025 – Kalaris Therapeutics had its “outperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/15/2025 – Kalaris Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Kalaris Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Kalaris Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/3/2025 – Kalaris Therapeutics is now covered by analysts at Citigroup Inc.. They set an “outperform” rating on the stock.
• 11/3/2025 – Kalaris Therapeutics is now covered by analysts at Citizens Jmp. They set a “market outperform” rating and a $20.00 price target on the stock.

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.